The proposed merger between Rallybio and the private firm Candid Therapeutics has drawn the attention of U.S. legal firms, casting doubt on the transaction’s fairness. Multiple law offices, including Brodsky & Smith and Kahn Swick & Foti, are investigating whether Rallybio’s board adequately protected shareholder interests during negotiations. Central to their inquiry is the equity stake remaining for current Rallybio investors, which is set at just 3.65% of the combined entity.
Sector Consolidation Provides Context
This scrutiny arrives during a period of intense consolidation within the biotechnology industry. In a significant move this Tuesday, Biogen announced its acquisition of Apellis Pharmaceuticals for $5.6 billion. Concurrently, Aurinia Pharmaceuticals moved to acquire Kezar Life Sciences. These deals reflect a broader trend where larger players are actively seeking clinical-stage assets to bolster their pipelines, particularly in rare diseases and autoimmune disorders.
Against this backdrop of sector-wide realignment, Rallybio’s operational challenges become more pronounced. The company reported annual revenue of only $858,000 and holds a market capitalization of approximately $46 million. Its precarious position was further highlighted earlier this year when a 1-for-8 reverse stock split was executed in February 2026 to maintain its Nasdaq listing and avoid delisting.
Should investors sell immediately? Or is it worth buying Rallybio?
Deal Structure and Market Reaction
The transaction is structured as a reverse merger, with the combined company expected to operate under the Candid Therapeutics name and trade under the ticker symbol CDRX. Completion is anticipated for mid-2026. Despite the ongoing legal reviews, Rallybio’s shares saw a modest increase of 1.99% in recent trading, closing at $8.20.
The core issue for investigators is whether the board conducted a fair process or if the existing shareholders are being shortchanged by the merger terms. The minimal 3.65% ownership stake for Rallybio’s current investors is the primary point of contention. Legal firms are examining if this valuation is justified or if it represents a disadvantage for the company’s equity holders.
These legal proceedings could potentially complicate the planned mid-2026 relaunch under the CDRX ticker. Management now faces the dual challenge of justifying the valuation to legal authorities while navigating a rapidly evolving and consolidating biotech landscape.
Ad
Rallybio Stock: Buy or Sell?! New Rallybio Analysis from April 1 delivers the answer:
The latest Rallybio figures speak for themselves: Urgent action needed for Rallybio investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 1.
Rallybio: Buy or sell? Read more here...
